• About us
• Contact

Advertisement

Organisation › Details

Inivata (Group)

Inivata is the liquid biopsy focused subsidiary of the NeoGenomics, Inc. (NASDAQ: NEO) Group. Inivata's InVision® liquid biopsy platform unlocks essential genomic information from a simple blood draw which may be used by clinicians to guide personalized cancer treatment, to monitor response to treatment and to detect relapse. The commercially available InVisionFirst®-Lung test offers highly sensitive testing and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata's personalized RaDaR® assay allows the highly sensitive detection of residual disease and recurrence in certain cancers and has been granted Breakthrough Device Designation by the US FDA. Inivata is partnering with pharmaceutical, biotechnology companies and commercial entities in early through late-stage cancer development programs across a range of cancer types. The InVisionFirst®-Lung test and RaDaR are laboratory developed tests (LDTs) performed by Inivata's CLIA certified, CAP accredited laboratory in Research Triangle Park, North Carolina, USA. Inivata also has R&D laboratories in Cambridge, UK. Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. *

 

	Start	2014-09-01 splitoff
	End	2021-05-05 acquired
	Group	NeoGenomics (Group)
	Today	NeoGenomics (Group)
	Successor	NeoGenomics (Group)
	Industry	RaDaR™ minimal residual disease assay
	Person	Stocum, Michael (Inivata 201603 CEO)
	Person 2	Rosenfeld, Nitzan (Inivata 201603 CSO)
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	The Portway Building Granta Park
	City	CB21 6GS Cambridge, Cambridgeshire
	Tel	+44-1223-790880
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: NeoGenomics, Inc.. (5/9/22). "Press Release: NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary". Ft. Myers, FL.
		Record changed: 2022-05-24

Advertisement

More documents for NeoGenomics (Group)

• [1] NeoGenomics, Inc.. (5/9/22). "Press Release: NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary". Ft. Myers, FL....
• [2] Inivata Ltd.. (4/28/21). "Press Release: Inivata and Agendia Sign Agreement for Commercialization of RaDaR MRD Liquid Biopsy Assay in Breast Cancer". Research Triangle Park, NC, Cambridge, Irvine, CA & Amsterdam....
• [3] Inivata Ltd.. (3/9/21). "Press Release: FDA Grants Breakthrough Device Designation for Inivata’s RaDaR Assay". Research Triangle Park, NC & Cambridge....
• [4] Inivata Ltd.. (2/4/21). "Press Release: Inivata Raises $35 million in Second Close of Series C Financing". Research Triangle Park, NC & Cambridge....
• [5] Inivata Ltd.. (9/22/20). "Press Release: Inivata Appoints Peter Collins as Chief Business Officer". Research Triangle Park, NC & Cambridge....
• [6] Inivata Ltd.. (4/16/19). "Press Release: Inivata, Thermo Fisher Scientific, and Genomics England Successfully Complete First Phase of Study Assessing Plasma Samples and Potential of Liquid Biopsy"....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.